News

Kymera’s partnerships with Sanofi and Gilead drive value
Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.
Zacks Investment Research on MSN3d
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...
Nasdaq3d
Kymera Therapeutics Announces $250.8 Million Public Offering of Common Stock and Pre-Funded Warrants - Nasdaq
Kymera Therapeutics, Inc. announced the pricing of its public offering of $250.8 million, consisting of 5,044,500 shares of common stock priced at $44.00 each, along with pre-funded warrants for ...
Medical Dialogues4d
Gilead Sciences, Kymera Therapeutics ink pact to develop novel oral molecular glue CDK2 degraders
Gilead Sciences, Inc. and Kymera Therapeutics, Inc., have entered into an exclusive option and license agreement for ...
Morningstar3d
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
Kymera Therapeutics Announces Pricing of $250 Million Public Offering Provided by GlobeNewswire Jun 27, 2025, 3:56:15 AM. WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera ...
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Seeking Alpha4d
KYMR Kymera Therapeutics, Inc. - Seeking Alpha
A high-level overview of Kymera Therapeutics, Inc. (KYMR) stock. View (KYMR) real-time stock price, chart, news, analysis, analyst reviews and more.
Kymera: Sanofi Ends KT-474 Work, Will Advance KT-485
Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.